Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials

Recently, Lin and colleagues assessed the safety of sodium-glucose cotransporter 2 inhibitors (SGLT2is) by a meta-analysis [1], in which the authors assessed 16 kinds of adverse events (AE) reported in the published articles based on 10 randomized controlled trials. We conducted a further meta-analy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mei Qiu, Li-Min Zhao, Ze-Lin Zhan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	SGLT2is safety cardiovascular diseases renal diseases asthma pneumonia Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/92f0a8df3a5f4ff69f8ca5684258a336
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92f0a8df3a5f4ff69f8ca5684258a336
record_format	dspace
spelling	oai:doaj.org-article:92f0a8df3a5f4ff69f8ca5684258a3362021-12-02T11:21:31ZComprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials1664-239210.3389/fendo.2021.743807https://doaj.org/article/92f0a8df3a5f4ff69f8ca5684258a3362021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fendo.2021.743807/fullhttps://doaj.org/toc/1664-2392Recently, Lin and colleagues assessed the safety of sodium-glucose cotransporter 2 inhibitors (SGLT2is) by a meta-analysis [1], in which the authors assessed 16 kinds of adverse events (AE) reported in the published articles based on 10 randomized controlled trials. We conducted a further meta-analysis and targeted the association between use of SGLT2is and occurrences of various kinds of serious AE published in the Clinical Trials website (clinicaltrials.gov). Our meta-analysis revealed that use of SGLT2is was not significantly associated with occurrences of 980 kinds of serious AE but was significantly associated with lower risks of 29 kinds of serious AE, especially including several important respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease, sleep apnoea syndrome, and pneumonia). These findings may cause more studies to evaluate the possibilities of gliflozins being used for prevention of these specific diseases.Mei QiuLi-Min ZhaoZe-Lin ZhanFrontiers Media S.A.articleSGLT2issafetycardiovascular diseasesrenal diseasesasthmapneumoniaDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENFrontiers in Endocrinology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SGLT2is safety cardiovascular diseases renal diseases asthma pneumonia Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	SGLT2is safety cardiovascular diseases renal diseases asthma pneumonia Diseases of the endocrine glands. Clinical endocrinology RC648-665 Mei Qiu Li-Min Zhao Ze-Lin Zhan Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
description	Recently, Lin and colleagues assessed the safety of sodium-glucose cotransporter 2 inhibitors (SGLT2is) by a meta-analysis [1], in which the authors assessed 16 kinds of adverse events (AE) reported in the published articles based on 10 randomized controlled trials. We conducted a further meta-analysis and targeted the association between use of SGLT2is and occurrences of various kinds of serious AE published in the Clinical Trials website (clinicaltrials.gov). Our meta-analysis revealed that use of SGLT2is was not significantly associated with occurrences of 980 kinds of serious AE but was significantly associated with lower risks of 29 kinds of serious AE, especially including several important respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease, sleep apnoea syndrome, and pneumonia). These findings may cause more studies to evaluate the possibilities of gliflozins being used for prevention of these specific diseases.
format	article
author	Mei Qiu Li-Min Zhao Ze-Lin Zhan
author_facet	Mei Qiu Li-Min Zhao Ze-Lin Zhan
author_sort	Mei Qiu
title	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
title_short	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
title_full	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
title_fullStr	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
title_full_unstemmed	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
title_sort	comprehensive analysis of adverse events associated with sglt2is: a meta-analysis involving nine large randomized trials
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/92f0a8df3a5f4ff69f8ca5684258a336
work_keys_str_mv	AT meiqiu comprehensiveanalysisofadverseeventsassociatedwithsglt2isametaanalysisinvolvingninelargerandomizedtrials AT liminzhao comprehensiveanalysisofadverseeventsassociatedwithsglt2isametaanalysisinvolvingninelargerandomizedtrials AT zelinzhan comprehensiveanalysisofadverseeventsassociatedwithsglt2isametaanalysisinvolvingninelargerandomizedtrials
_version_	1718395950978826240

Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials

Ejemplares similares